Epigenetic editing goes from concept to clinic in biotech startups
A new wave of biotech startups is pursuing targeted epigenetic editing—modifying DNA-associated chemical markers to turn genes on or off—aiming to treat diseases from muscular dystrophy to hepatitis B; companies like Epicrispr and nChroma are leading with dead-Cas9/Cas12F tools and refined methyltransferases, reporting preclinical success and early human dosing, while researchers caution that long‑term safety and off‑target effects remain critical as this approach moves toward the clinic.